Human embryonic stem cell derived oligodendrocyte progenitor cells (hESC-derived OPCs) have therapeutic potential in several neurological disorders that affect myelin in the human nervous system including: Spinal Cord Injury (SCI), Adenoleukodystrophy, Radiation injury, Multiple Sclerosis, and Huntington’s Disease (HD). This award supported the development of a scalable manufacturing process of purified hESC-derived OPCs to meet the high patient demand of such therapy.